Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice

Acute kidney injury (AKI) is a common reactive oxygen species (ROS)-related renal disease that causes numerous deaths annually, yet only supportive treatment is currently available in the clinics. Development of antioxidants with high accumulation rates in kidneys is highly desired to help prevent A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Dalong, Jiang, Dawei, Kutyreff, Christopher J., Lai, Jianhao, Yan, Yongjun, Barnhart, Todd E., Yu, Bo, Im, Hyung-Jun, Kang, Lei, Cho, Steve Y., Liu, Zhaofei, Huang, Peng, Engle, Jonathan W., Cai, Weibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303396/
https://www.ncbi.nlm.nih.gov/pubmed/30575745
http://dx.doi.org/10.1038/s41467-018-07890-8
Descripción
Sumario:Acute kidney injury (AKI) is a common reactive oxygen species (ROS)-related renal disease that causes numerous deaths annually, yet only supportive treatment is currently available in the clinics. Development of antioxidants with high accumulation rates in kidneys is highly desired to help prevent AKI. Here we report molybdenum-based polyoxometalate (POM) nanoclusters with preferential renal uptake as novel nano-antioxidants for kidney protection. These POM nanoclusters, with a readily variable valence state of molybdenum ions, possess the capability to scavenge detrimental ROS. Our results demonstrate that POM nanoclusters can efficiently alleviate clinical symptoms in mice subjected to AKI, as verified by dynamic PET imaging with (68)Ga-EDTA, serum tests, kidney tissue staining, and biomarkers detection in the kidneys. The protective effect of POM nanoclusters against AKI in living animals suggests exploring their use for the treatment of AKI patients, as well as patients with other ROS-related diseases.

Ejemplares similares